Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Population pharmacokinetics.

L Aarons1

  • 1Pharmacy Department, University of Manchester, UK.

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Traditional drug development studies use small, healthy groups, yielding limited target population data. New methods analyze sparse data from later-stage trials, improving pharmacokinetic and pharmacodynamic insights.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Constrained numerical deconvolution using orthogonal polynomials.

Heliyon·2024
Same author

Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose.

British journal of pharmacology·2017
Same author

Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.

CPT: pharmacometrics & systems pharmacology·2017
Same author

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Clinical pharmacology and therapeutics·2017
Same author

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients.

Mathematical medicine and biology : a journal of the IMA·2017
Same author

Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.

Clinical pharmacology and therapeutics·2014
Same journal

Distribution of lidocaine and digoxin in heart tissues and aorta following intrapericardial administration.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.

International journal of clinical pharmacology, therapy, and toxicology·1993
Same journal

Effect of DL-sodium lactate infusion on excretion of purine bases and oxypurinol.

International journal of clinical pharmacology, therapy, and toxicology·1993
See all related articles

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Drug Development
  • Clinical Trial Design

Background:

  • Traditional pharmacokinetic studies utilize small, homogenous groups, primarily healthy young males, providing controlled baseline data.
  • Concerns exist regarding insufficient early data collection within the actual target patient population during drug development.
  • Phase III studies present logistical challenges, lack control, and generate sparse data, limiting kinetic and dynamic information.

Purpose of the Study:

  • To discuss the issues and problems associated with traditional pharmacokinetic study designs.
  • To explore the current status and growing interest in techniques for analyzing sparse data.
  • To highlight the increasing pressure on manufacturers to gather more kinetic and dynamic information from Phase III studies.

Related Experiment Videos

Main Methods:

  • Review of traditional pharmacokinetic study methodologies.
  • Analysis of challenges in Phase III clinical trial data collection.
  • Discussion of emerging techniques for sparse data analysis.

Main Results:

  • Traditional methods provide controlled baseline data but lack target population relevance.
  • Phase III studies are logistically difficult and yield sparse, uncontrolled data.
  • There is a growing need and developing interest in methods to analyze sparse data.

Conclusions:

  • There is a critical need to improve pharmacokinetic and pharmacodynamic data collection in target populations.
  • Population-based studies and sparse data analysis techniques are essential for modern drug development.
  • Future research should focus on optimizing methods for extracting kinetic and dynamic information from limited datasets.